LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

59.44 1.55

Buy Sell

Overview

Share price change

24h

Current

Min

57.13

Max

60.6

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+38.36% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	441M 2B
Previous open	57.89
Previous close	59.44

News Sentiment

By Acuity

39%

61%

121 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 maj 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 maj 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 maj 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 maj 2026, 23:28 UTC

Market Talk

Earnings

Global Forex and Fixed Income Roundup: Market Talk

19 maj 2026, 23:28 UTC

Market Talk

Earnings

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 maj 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 maj 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 maj 2026, 22:02 UTC

Earnings

ZTO Express (Cayman): Di Xu to Resign From Board

19 maj 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 maj 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 maj 2026, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 maj 2026, 21:37 UTC

Earnings

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 maj 2026, 21:01 UTC

Earnings

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 maj 2026, 20:58 UTC

Earnings

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 maj 2026, 20:46 UTC

Hot Stocks

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 maj 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 maj 2026, 20:34 UTC

Earnings

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q EPS 5c >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q Sales $1.4B >JHX

19 maj 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 maj 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 maj 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 maj 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 maj 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 maj 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 maj 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 maj 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 maj 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

38.36% upside

12 Months Forecast

Average 81.27 USD 38.36%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

121 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.